Navigation Links
Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
Date:5/27/2008

VANCOUVER and SAN DIEGO, May 27 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, is taking aggressive steps to further reduce expenses to extend its cash runway through the Omigard(TM) Phase III results milestone expected in the second half of 2008 while continuing to focus on advancing the Company's MX-2401 program. Efforts are also underway to raise additional cash which will be required to enable continued key development activities expected to maximize long-term shareholder value and extend the Company's cash position into 2009.

The cost reduction actions include some limited program-related changes, substantial management and board compensation cuts, personnel reductions, and other operational streamlining activities (see "SPECIFIC COST-CUTTING ACTIONS" below).

Jim DeMesa, M.D., President and CEO of MIGENIX stated, "We must preserve our cash during this very difficult financial market for biotech companies. With the significant value-driving milestones we expect during the second half of this year and the first half of next year - along with the potential start of Omigard(TM) related revenues - we must take these actions to extend our cash runway as long as possible while continuing to advance our greatest product opportunities. These actions are expected to achieve both. All of us at MIGENIX are committed to creating value for our shareholders, advancing our pipeline of promising drug candidates and improving lives."

As a result of these initiatives, the following are our potential milestones over the next 12 months:

Omigard(TM) (prevention of catheter-related infections):

--------------------------------------------------------

- Positive Phase III results in H2/08

- NDA submission in H1/09, with the associated milestone payments

- Completion of rest of world partnership(s), with associated up-front

paymen
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
(Date:7/24/2014)... research team led by group leader Yung-Eun Sung ... to synthesize sulfur-doped and nitrogen-doped graphenes which can ... batteries and fuel cells. Yung-Eun Sung is both ... Research at Institute for Basic Science* (IBS) and ... This achievement has great significance with regards to ...
(Date:7/24/2014)... Engineering at the University of Delaware, is known ... energy engineering, environmental sustainability and electronics. , His ... with a well-defined, crystalline structure. At the atomic ... that zeolites can separate molecules with size differences ... of a nanometer), making them useful to the ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2
... 10 MedImmune today announced that,researchers will present ... the Annual Meeting of the American Association for,Cancer ... oncology research., "Cancer research has long been ... we,are proud to share data from our increasingly ...
... NEW YORK, April 10 Intellect Neurosciences,Inc. (OTC ... obtained a,Notice of Allowance and completed the grant ... Company,s ANTISENILIN(R) antibodies and,products being developed by the ... the European patent is expected in several weeks. ...
... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals, ... the Chairman and,Ranking Member of the U.S. House ... of legislation to establish a Follow-On,Biologics (FOBs) regulatory ... the biotechnology industry,healthcare and patient communities, the letter ...
Cached Biology Technology:MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 2MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... biodiversity, the product of 3.5 billion years of evolutionary ... of life. But it may be reaching a tipping ... and analysis of data published in Science , ... and decline of animals is contributing to what appears ... mass biological extinction event. , Since 1500, more than ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva ... Fox Foundation for Parkinson,s Research to translate a basic ... drug discovery project will test chemical compounds on a ... drug that acts on an underlying cause of the ... many people manage their symptoms, we are eager to ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... a mathematical model of how cells pack together to form ... no model is universal. Researchers at Northwestern University have ... -- to show how cells pack together to create the ... hope that the pared-down equation can be applied to different ...
... Louis is partnering with Chrysler LLC and a ... if paint solid residues from automobile manufacturing can reduce ... project is based upon the technical expertise of Pratim ... Engineering Science, who has demonstrated the effectiveness of titanium ...
... Nucleonics, Inc., a privately held biotechnology company ... (RNAi)-based therapeutics, announced today that the company has ... safety study of its experimental treatment for chronic ... NUC B1000 ( http://www.nucleonicsinc.com/products/hepb.html ) is an ...
Cached Biology News:Researchers create mathematical model of fruit fly eyes 2Washington University, 2 industries, team to clean up mercury emissions 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Calf Serum; U.S. sourced, ideal ... uncompromising quality; Low hemoglobin; Endotoxin: ... animals of US origin; U.S. ... seek an uncompromising quality. Low ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Biology Products: